Program
BR1015
A development code. Also written as “BR1015-A”.
Its studies are mostly in Essential Hypertension · Hypertension, led by Boryung Pharmaceutical.
Furthest: phase 1, since Aug 16, 202310 company-led studies, 4 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boryung Pharmaceutical | 104 open or running | phase 1since Aug 16, 2023 | Aug 16, 2023 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2023First studies: 2 phase 1 studies in HypertensionFirst studyNCT06008028, NCT06008015
- Dec 17, 20244 phase 1 studies in Essential HypertensionNCT06744439, NCT06744426, NCT06744127 and 1 more
- Feb 12, 20264 phase 1 studies in Essential HypertensionNCT07421414, NCT07421401, NCT07421388 and 1 more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07421414Essential Hypertension | 1 | Not yet recruiting | Jun 17, 2026 | 48 |
| NCT07421401Essential Hypertension | 1 | Not yet recruiting | Jun 11, 2026 | 58 |
| NCT07421388Essential Hypertension | 1 | Not yet recruiting | Jun 7, 2026 | 48 |
| NCT07421375Essential Hypertension | 1 | Not yet recruiting | May 31, 2026 | 58 |
| NCT06744439Essential Hypertension · Korea, Republic of | 1 | Completed | Mar 16, 2025 | 49 |
| NCT06744426Essential Hypertension · Korea, Republic of | 1 | Completed | Mar 12, 2025 | 60 |
| NCT06744127Essential Hypertension · Korea, Republic of | 1 | Completed | Mar 14, 2025 | 58 |
| NCT06744062Essential Hypertension · Korea, Republic of | 1 | Completed | Mar 19, 2025 | 48 |
| NCT06008028Hypertension · Korea, Republic of | 1 | Completed | Oct 6, 2023 | 57 |
| NCT06008015Hypertension · Korea, Republic of | 1 | Completed | Oct 3, 2023 | 44 |
How it is read
Names in the registry
- “BR1015”, 6 entries
- “BR1015-A”, 4 entries
Codes read as this program: BR1015.
Conditions, from the studies’ own filings
- Essential Hypertension, 8 studies
- Hypertension, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.